Abstract:
The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
Disclosed is a pyrimidine compound of Formula (I) wherein Cy1 is cycloalkyl, heterocycIyl, cycloalkenyl, heterocyclenyl, heteroaryl, aryl, or multicyclic alkaryl. Cy2 is cycloalkenyl, heterocyclenyl, aryl, heteroaryl, or multicyclic alkaryl. L1 is a straight- or branched-chain alkylene or a -CH2-haloalkylene, or is cycloalkylene or L1 and Cy2 together represent arylcycloalkyl or cycloalkylaryl. R1 is alkoxy, L2 is bond, -O- or -CH2-O- and wherein R2, R3, R4 and R5 are each independently H or alkyl. R6 is alkyl, R7 is H or alkyl and R8 is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl. Y1 and Y2 are each independently hydrogen, or alkyl or Y1 and Y2 taken together with the nitrogen atom to which they are attached, form a nitrogen containing three to seven member saturated heterocyclyl. Z1 is C(=O)-N(R4), NR4 or S(O)n and n is 0, 1 or 2 or an N-oxide thereof and R4 is as defined in the specification, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also disclosed are pharmaceutical compositions comprising said compound and the use of said compound in the manufacture of a medicament for the treatment of an allergic disorder e.g. asthma.
Abstract:
The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
Un compuesto de Fórmula (I) donde: (A) Cy1 es cicloalquilo C3-10, heterociclilo de 3-10 miembros, cicloalquenilo C3-10, heterociclenilo de 3-10 miembros, heteroarilo de 5-14 miembros, arilo-C6-14 o alcarilo multicíclico, cada uno de los mismos está sustituido con uno a tres de los siguientes grupos de sustituyentes de Cy1 iguales o sustituyentes que consisten en: formil-alquil C1-20-C(>=O), alquenil-C2-15-C(>=O), alquinil-C2-15-C(>=O), cicloalquil-C3-10-C(>=O), cicloalquenil C3-10-C(>=O), heterociclilo de 3-10 miembros-C(>=O), heterociclenilo de 3-10 miembros C(>=O), ciano, halógeno, 10 nitro, carboxi, hidroxi, alquiltio-C1-20, alquilsulfonilo C1-20, alquilsulfinilo C1-20, cicloalquilo-C3-10, heterociclilo de 3-10 miembros , cicloalquenilo C3-10, heterociclenilo de 3-10 miembros , arilo-C6-14, heteroarilode 5-14 miembros , alcarilo multicíclico, aroílo-C6-14, aril C6-14-alcoxicarbonilo C1-20, aril-C6-4-alquiltio-C1-20, ariloxi-C6-14, ariloxicarbonilo C6-14, arilsulfinilo C6-14, arilsulfonil C6-14, ariltio C6-14, heteroariloxi de 5-14 miembros, heteroarilalcoxicarbonilo de 5-14 miembros, N-metoxisulfamoilo, R2-C(>=N-OR3)-, Y1Y2N-, Y1Y2NC(>=O)-, Y1Y2NC(>=O)-O-, Y1Y1NSO2-, alquil C1-20-O-C(>=O)-alquilen (C2-C6)-Z1-, Y1Y2N-C(>=O)-alquilen-(C1-C6)-Z1-, Y1Y2N-alquilen-(C2-C6)-Z1-, alquil C1-20-C(>=O)-N(R5)-SO2-, alquil-C1-20-O-C(>=O)-N(R5)-, alquil C1-20-O-C(>=O)-N(R5)-SO2-, alquil C1-20-O-N(R5)-SO2-, alquil C1-20-O-N(R5)-C(>=O)-, alquil C1-20-SO2-N(R5)-C(>=O)-, aril C6-14-SO2- N(R5)-C( >=O)-, alquil C1-20-SO2-N(R5)-, R6-C(>=O)-N(R5)-, R7 -NH-C(>=O)-NH-; alquenilo C2-15, que está opcionalmente sustituido con alcoxi C1-20 o hidroxi; alcoxicarbonilo C1-20, que está opcionalmente sustituido con Y1Y2N-; alquinilo C2-15, que está opcionalmente sustituido con hidroxi o alcoxi C1-20; alquilo C1-20, que está opcionalmente sustituido con uno a tres de halógeno, carboxi, ciano, hidroxi, Y1Y2N-, Y1Y2N-C(>=O)-, H2N-C(>=NH)-NH-O-, R6 -C(>=O)-N(R5)-, alquil-C1-20-O-C(>=O)-N(R5)-, alquil-C1-20-SO2-N(R5)-, R8-SO2-N(R5)-C(>=O)-, aril C6-14-N(R5)-C(>=O)-, heteroaril de 5-14 miembros-N(R5)-C(>=O)-, heterciclilo de 3-25 10 miembros-N(R5)-C(>=O)-, alcoxicarbonilo-C1-20, cicloalquil-C1-20, heterociclilo de 3-10 miembros, cicloalquenilo-C3-10, heterociclenilo de 3-10 miembros, arilo-C6-14, heteroarilo de 5-14 miembros, alcarilo multicílcico, iguales o diferentes; alcoxi-C1-20, que está opcionalmente sustituido con carboxi, aril-C6-14 o heteroarilo de 5-14 miembros; o alcoxicarbonilo C1-20, que está opcionalmente sustituido con Y1Y2N-; y alcoxi-C1-20, que está opcionalmente sustituido con uno a tres de carboxi, alcoxicarbonilo-C1-20, ciano, 30 halógeno, -NY1Y2, Y1Y2N-C(>=O)-, cicloalquilo-C3-10, heterociclilo de 3-10 miembros , cicloalquenilo C3-10, heterociclenilo de 3-10 miembros, arilo-C6-14, heteroarilo de 5-14 miembros o alcarilo multicíclico, iguales o diferentes; en la que los restos arilo-C6-14 o heteroarilo de 5-14 miembros en los grupos de sustituyentes de Cy1 están 35 opcionalmente sustituidos con hidroxi, amino, alquilo-C1-20, alcoxi-C1-20, carboxi, alcoxicarbonil-C1-20 o R8-SO2-N(R5)-C(>=O)-; y donde los restos cicloalquilo-C3-10, cicloalquenil-C3-10, heterociclilo de 3-10 miembros, heterociclenilo de 3-10 miembros o alcarilo multicíclico en el grupo de sustituyentes de Cy1 están opcional e independientemente 40 sustituidos con hidroxi, amino, alquilo-C1-20, alcoxi-C1-20, oxo, carboxi, alcoxicarbonilo-C1-20 o R8-SO2-N(R5)-C(>=O)-.
Abstract:
The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
La presente invencion se refiere a un compuesto de Formula (I) en la que Cy1, Cy2, L1, L2 y R1 son como se definen en este documento, a una composicion farmaceutica que comprende una cantidad farmaceuticamente eficaz de uno o mas compuestos de acuerdo con la Formula (I) en mezcla con un vehiculo farmaceuticamente aceptable, a un metodo para tratar a un paciente que padece un trastorno mediado por la PGD2 incluyendo, pero sin limitacion, asma bronquial, enfermedad pulmonar obstructiva cronica (COPD), rinitis alergica, dermatitis alergica, conjuntivitis alergica, bronquitis, mastocitosis sistemica y lesion de reperfusion isquemica por medio de la administracion a dicho paciente de una cantidad farmaceuticamente eficaz de un compuesto de acuerdo con la Formula (I).
Abstract:
The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to metho ds of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or preventi on of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.